flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Effects of Semaglutide With or

Wilson disease is caused by a genetic defect that allows copper to accumulate in the liver and other organs

The FDAs stark warning coincides with Hollywoods Ozempic craze that has snowballed in recent months, as researchers concoct rival weight-loss injectables amid growing demand

Dont wait until youve lost significant weight to start thinking about muscle preservationstart protecting your muscle mass immediately

Ribosomal protein L19 (Rpl19) was used as a reference gene to normalize the mRNA levels

Sermorelin has prior FDA approval history

A Lithium GLP-1 Interaction More evidence of a serious drug interaction STUDY: Patarroyo-Rodriguez LP et al, J Clin Psychopharmacol 2026 STUDY TYPE: Case report FUNDING: National Center for Advancing Translational Science (NCATS) Background GLP-1 and GIP/GLP-1 receptor agonists like tirzepatide (Mounjaro, Zepbound) cause nausea, vomiting, and dehydration, especially during dose escalation